Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin - Wikidata - wikimedia - TriplyDB

Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin

Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin

http://www.wikidata.org/entity/Q33302297

about

Research resource: Haploinsufficiency of receptor activity-modifying protein-2 (RAMP2) causes reduced fertility, hyperprolactinemia, skeletal abnormalities, and endocrine dysfunction in mice Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular system Calcitonin gene-related peptide: physiology and pathophysiology Proinflammatory mediators and migraine pathogenesis: moving towards CGRP as a target for a novel therapeutic class Endosomal proteolysis regulates calcitonin gene-related peptide responses in mesenteric arteries Calcitonin gene-related peptide receptor antagonists for the treatment of migraine: a patent review.Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974).Discovery of BMS-846372, a Potent and Orally Active Human CGRP Receptor Antagonist for the Treatment of Migraine Analysis of the proteolysis of bioactive peptides using a peptidomics approach.The Dose Proportionality of Telcagepant after Administration of Single Oral and Intravenous Doses in Healthy Adult Subjects CGRP receptor antagonists: an expanding drug class for acute migraine?ACS chemical neuroscience molecule spotlight on Telcagepant (MK-0974).Inhibition of calcitonin gene-related peptide function: a promising strategy for treating migraine Quinoline derivatives: candidate drugs for a class B G-protein coupled receptor, the calcitonin gene-related peptide receptor, a cause of migraines.Calcitonin gene-related peptide receptor antagonists for migraine.Targeting a family B GPCR/RAMP receptor complex: CGRP receptor antagonists and migraine.CGRP receptor antagonists: design and screening.Asymmetric organocatalysis at the service of medicinal chemistry CGRP antagonists and antibodies for the treatment of migraine.Novel strategies for the treatment of migraine attacks via the CGRP, serotonin, dopamine, PAC1, and NMDA receptors.Discovery of MK-3207: A Highly Potent, Orally Bioavailable CGRP Receptor Antagonist Inhibition of nitric oxide synthesis in mouse macrophage cells by feverfew supercritical extract.[(11)C]MK-4232: The First Positron Emission Tomography Tracer for the Calcitonin Gene-Related Peptide Receptor Control of olefin geometry in macrocyclic ring-closing metathesis using a removable silyl group.Effect of the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human cranial arteries.Single- and multiple-dose pharmacokinetics and tolerability of telcagepant, an oral calcitonin gene-related peptide receptor antagonist, in adults.Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats.Telcagepant is a new oral treatment for migraine.Lack of hemodynamic interaction between CGRP-receptor antagonist telcagepant (MK-0974) and sumatriptan: results from a randomized study in patients with migraine.Calcitonin gene-related peptide and migraine with aura: A systematic review.A randomized, placebo-controlled study of the effects of telcagepant on exercise time in patients with stable angina.

P2860

Q24603724-39F9EDFE-7FC7-49A7-A4A4-E41FB9E591AD Q24632671-88C7927E-0D6F-4CB4-9EFE-0540D68F9182 Q24646305-6718E030-598A-4ADE-8F68-7608685E19FE Q28249298-8061C6E2-BEB8-4354-8CB3-D8D5408642B8 Q28292548-05BEBA80-6F22-443F-B0B9-AC9D5BFBC511 Q28577195-E26650B8-4730-4D2F-B53E-B29A4DD165D1 Q33516651-94D1FD64-C0C7-4DCB-8D18-15FBFDA11862 Q33524521-62C2E2A9-F36A-4B17-AE13-282F244E5924 Q33630515-17EB64CF-1720-46C4-9101-224D8F48EAF8 Q34222114-0A7C1F7C-181C-4161-9FD7-A4C78FC88BB8 Q34462428-0CE7524A-31CC-43E4-89A8-327BED6D8824 Q34637610-4B4E8952-258E-4B9E-BCD9-B92909857093 Q36015430-D8145D75-55F9-4983-A010-8D518299B196 Q37276146-5BA138CB-9356-4B1E-B3C9-87DAE38651A1 Q37546168-ABED9C7F-F7D5-4853-AC96-7A07BDE8BD42 Q37756158-A7158284-E25B-4725-B15D-08B481344A94 Q37922799-D56288AA-2D18-4D78-A761-1BE4AD39742E Q38088346-FE8F3AE9-14D1-40FA-B3AB-C050F97648A1 Q38223762-D495DB0D-8471-4A59-AE62-BD4C9210344B Q38248953-FAF907D2-7CD8-43C9-AFFD-4362C3FB3D30 Q38254099-C7DC0D8D-5D8E-4469-B587-6516D7065B6A Q39155929-6BCAC84B-1FDD-450F-98F9-F31C94862AB7 Q39471974-598162C6-3C85-41EC-82DC-91F25894A90C Q39769257-58C73E6D-ADE1-4E66-8D1F-BB1F2968F427 Q41966027-08BB7D0B-B83D-4D8B-9EF3-BAF1E19EF3ED Q42882636-D14ED29A-A7D7-461A-86EB-F2FD71ECAB91 Q43155089-54DAAE8A-7D3C-4680-9F38-B9F101A7879F Q45948485-F70BB3CA-8EC3-4AC5-BFE3-0DEEBBC92D03 Q45978359-15610055-D0DD-4F94-A51D-39C1109E05C1 Q46077794-F2EBD505-8653-486E-A91E-4A0596EB2628 Q48366274-052A0A24-3A50-44C1-841F-42CF8A1979FB Q48745119-ED195392-F807-41EA-8E8C-4F80B45A1826

P2860

Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin

http://www.wikidata.org/entity/Q33302297

description

2007 nî lūn-bûn

@nan

2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Potent, orally bioavailable ca ...... hydro-1H-imidazo[4,5-b]pyridin

@ast

Potent, orally bioavailable ca ...... hydro-1H-imidazo[4,5-b]pyridin

@en

Potent, orally bioavailable ca ...... hydro-1H-imidazo[4,5-b]pyridin

@nl

type

label

Potent, orally bioavailable ca ...... hydro-1H-imidazo[4,5-b]pyridin

@ast

Potent, orally bioavailable ca ...... hydro-1H-imidazo[4,5-b]pyridin

@en

Potent, orally bioavailable ca ...... hydro-1H-imidazo[4,5-b]pyridin

@nl

prefLabel

Potent, orally bioavailable ca ...... hydro-1H-imidazo[4,5-b]pyridin

@ast

Potent, orally bioavailable ca ...... hydro-1H-imidazo[4,5-b]pyridin

@en

Potent, orally bioavailable ca ...... hydro-1H-imidazo[4,5-b]pyridin

@nl

P1433

Q33302297-B8F0A7E3-71BA-4692-8839-EB62124707FA

P1476

Q33302297-99BFE13C-6BDC-4665-BC37-C5A80C4A2EDA

P2093

Q33302297-04960D72-3737-4268-868B-87F6AA29424E

Q33302297-212FD7C0-F8DA-4439-AFC1-C713B84CE07D

Q33302297-27139703-C866-491B-990E-D4858AACCEC2

Q33302297-63B25EA6-80A1-46FB-8736-D2E67C087F2D

Q33302297-6B0BCF89-30FE-45EF-8574-7F1A5636E997

Q33302297-7361EFBA-D6EC-4E1D-938D-A0A5363A6578

Q33302297-78913C89-EA0D-444C-B23B-8603D28CD542

Q33302297-7D8E2A66-9B4E-4D05-8178-90A83E345871

Q33302297-82B2CFFA-5F27-41F4-96EF-F6FE24CA4C79

Q33302297-98140F7A-35DA-4204-9D5E-50BE68E17036

P304

Q33302297-E33F664B-B8B5-4E2A-8E3F-1D0B1FFA1BFA

P31

Q33302297-2AB94396-5AC5-4BE5-81B1-6543FFBE98BC

P356

Q33302297-A03ACF5D-3FD4-4C9B-A1D4-6869B061B7AF

P407

Q33302297-A02C714D-2CE2-4315-B262-1638B417488F

P433

Q33302297-68B0FC44-6F4B-4E3A-8187-DAC501496B95

P478

Q33302297-11E51CBD-6B62-452E-B160-D952F4DA5183

P577

Q33302297-30E06F1D-E53A-468F-9397-498D242D810E

P698

Q33302297-F231CA83-3418-49A5-B90B-EE350753A602

P921

Q33302297-6F5C1610-C42F-4799-8CB4-410BCFBF5BA6

P356

P1433

Journal of Medicinal Chemistry

P1476

Potent, orally bioavailable ca ...... hydro-1H-imidazo[4,5-b]pyridin

@en

P2093

Anthony W Shaw

http://www.w3.org/2001/XMLSchema#string

Bradley K Wong

http://www.w3.org/2001/XMLSchema#string

Christopher A Salvatore

http://www.w3.org/2001/XMLSchema#string

Christopher S Burgey

http://www.w3.org/2001/XMLSchema#string

Cynthia M Miller-Stein

http://www.w3.org/2001/XMLSchema#string

Daniel V Paone

http://www.w3.org/2001/XMLSchema#string

Diem N Nguyen

http://www.w3.org/2001/XMLSchema#string

James C Hershey

http://www.w3.org/2001/XMLSchema#string

James Z Deng

http://www.w3.org/2001/XMLSchema#string

Joseph P Vacca

http://www.w3.org/2001/XMLSchema#string

P304

5564-5567

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/JM070668P

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P577

2007-10-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17929795

http://www.w3.org/2001/XMLSchema#string

P921

migraine disorder